Canadian Institutes of Health Research
Français Contact UsHelpSearchCanada Site
CIHR HomeAbout CIHRWhat's NewFunding OpportunitiesFunding Decisions
CIHR | IRSC
About CIHR
CIHR Institutes
Funding Health Research
Funding News and Developments
Funding Opportunities
How to Apply for Funding
CIHR Funding Policy
Peer Review
Funding Decisions
Funding Related Databases
Training Opportunities
ResearchNet
Knowledge Translation and Commercialization
Partnerships
Major Strategic Initiatives
International Cooperation
Ethics
News and Media
Publications
 

Research Chairs - GlaxoSmithKline Inc. Partnered - Application Package

Deadlines for Application: February 15th, April 15th, July 15th, September 1st or November 1st.

Number of Copies: The original, plus eight (8) additional copies are required.
 
Note: To ensure that your registration and application are forwarded to the appropriate CIHR staff, indicate "CIHR/Rx&D Research Program GSK-CIHR Research Chair" under the heading "Name of Industrial Partner(s) OR Partnership Program OR Special Program " in the General Information section of the Research Module (page 7 of the PDF form).

Application Process:

1. Complete the full application using the Industry-Partnered Research Chairs Full Application package which consists of the Common CV, the CIHR Research Module (including an eleven (11)-page research proposal); and, if applicable, the CIHR Operating Budget Module (if applying for equipment or operating funds). Additional Common CVs are required for any co-applicants participating in the research project described in the operating grant application.

2. The Industrial Partnership Module is not required, because an RFA has been issued.

3. When completing the CIHR Operating Budget Module, provide a detailed justification of all project costs. Costs to be covered by CIHR's funding partners should be listed in the "Other Funding Sources" column on Page 1 of the Budget Module.

4. Full applications must be accompanied a Nominating Letter to be accepted at CIHR. The Nomination Letter must include the following:

  1. Confirmation of the execution of the endowment contract between GSK and the Nominating institution.
  2. Confirmation by the Nominating institution of a cash flow from the endowment that will support the Salary component of the Award at a level that is commensurate with the incumbent's experience and with institutional policies. Typically, a confirmed cash flow (excluding CIHR funds) of $250,000 to $350,000 over five years earmarked to support the Salary is anticipated.
  3. Confirmation by the Nominating institution that the Salary component of the Award and its level will be maintained after the term of CIHR funding as long as the incumbent remains at the nominating institution.
  4. Relevant information on the contributors (private, public and NGO sector) to the endowment (or cash contribution) and a breakdown of the proportion of the endowment that is provided by GSK and, other contributors (to endowment or cash).


Created: 2005-04-26
Modified: 2006-01-05
Reviewed: 2005-04-26
Print